Insights
Search Results
Client Highlights
3.28.24
Wilson Sonsini Advises Stoke Therapeutics on IP Matters Related to Upsized Public Offering
On March 28, 2024, Stoke Therapeutics, a biotechnology company focused on developing RNA-based medicines to treat severe diseases, announced the pricing of its upsized underwritten public offering. The company is offering 5,555,557 shares at $13.50 per share and, in lieu of shares to investors that so choose, pre-funded warrants to purchase up to 3,703,730 shares at $13.4999. Stoke has also granted the underwriters a 30-day option to purchase up to an additional 1,388,893 shares. The gross proceeds from this offering, to be closed on or about April 2, are expected to be $125 million before expenses. Wilson Sonsini Goodrich & Rosati advised Stoke on IP matters related to the transaction.
Client Highlights
2.02.22
Wilson Sonsini Advises Stoke Therapeutics on IP Matters Related to Collaboration with Acadia Pharmaceuticals
On January 10, 2022, Acadia Pharmaceuticals and Stoke Therapeutics announced that the companies have entered a collaboration to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS), including SYNGAP1 syndrome, Rett syndrome (MECP2), and an undisclosed neurodevelopmental target of mutual interest. Wilson Sonsini Goodrich & Rosati advised Stoke Therapeutics on IP matters related to the collaboration.
Client Highlights
7.10.20
Wilson Sonsini Advises on IP for Stoke Therapeutics’ $400 Million Offering
On July 10, 2020, Stoke Therapeutics filed a prospectus for a $400 million mixed shelf offering of its common stock, preferred stock, debt securities, warrants, and subscription rights and units. The company's stock is traded on the Nasdaq Global Select Market under the symbol “STOK.” On July 8, 2020, the last reported sales price for Stoke Therapeutics' common stock was $23.40 per share. Wilson Sonsini Goodrich & Rosati advised Stoke Therapeutics on all intellectual property aspects related to the offering.
Client Highlights
6.25.20
Wilson Sonsini Advises Orca Biosystems in Patent Matters Related to $192 Million Series D
On June 17, 2020, Orca Bio closed a Series D financing round worth $192 million, bringing the total raised since 2016 to $300 million. The round was co-led by Lightspeed Venture Partners and an undisclosed investor. New and existing investors included 8VC, DCVC Bio, ND Capital, Mubadala Investment Company, Kaiser Foundation Hospitals, Kaiser Permanente Group Trust, and IMRF. Wilson Sonsini Goodrich & Rosati represented Orca Bio in patent matters related to the transaction.